摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(4-methoxybenzyl)-2,6-dimethyl-3H-pyrimidin-4-one | 27032-79-7

中文名称
——
中文别名
——
英文名称
5-(4-methoxybenzyl)-2,6-dimethyl-3H-pyrimidin-4-one
英文别名
5-[(4-methoxyphenyl)methyl]-2,6-dimethyl-1H-pyrimidin-4-one
5-(4-methoxybenzyl)-2,6-dimethyl-3H-pyrimidin-4-one化学式
CAS
27032-79-7
化学式
C14H16N2O2
mdl
——
分子量
244.293
InChiKey
ATSDRPHPOYDFTN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    168-169 °C
  • 沸点:
    389.1±44.0 °C(Predicted)
  • 密度:
    1.15±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    50.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor
    申请人:Nishimura Toshihiro
    公开号:US20050049203A1
    公开(公告)日:2005-03-03
    The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X 1 and X 3 independently represent N or CH; X 2 represents N or CR 2 ; X 4 represents N or CR 3 ; and with the proviso that one or two of X 1 , X 2 , X 3 and X 4 represent N; R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted(lower alkoxy) group, a lower alkoxy(lower alkoxy) -substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A—wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R 3 represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, or prodrugs thereof which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses and production intermediates thereof.
    本发明提供了一种以通式表示的含氮杂环衍生物: 其中,X1和X3独立地表示N或CH;X2表示N或CR2;X4表示N或CR3;并且假定X1、X2、X3和X4中的一个或两个表示N;R1表示氢原子、卤素原子、低碳基、低烷氧基、低代烷基、低烷氧基取代的(低烷基)基团、低烷氧基取代的(低烷氧基)基团、低烷氧基(低烷氧基)取代的(低烷基)基团、环状低烷基、卤素(低烷基)基团或由通式HO-A-表示的基团,其中A表示低碳亚烷基、低碳亚烷氧基或低碳亚烷基;R2表示氢原子、卤素原子、低碳基、环状低碳基、低烷氧基、基、(低酰基)基、单(低烷基)基或双(低烷基)基;R3表示氢原子或低碳基,或其药学上可接受的盐,或其前药,其作为预防或治疗与高血糖相关的疾病,如糖尿病、糖尿病并发症或肥胖症的药剂,包括这些药剂的制剂和制备中间体。
  • Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:US07271153B2
    公开(公告)日:2007-09-18
    The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 and X3 independently represent N or CH; X2 represents N or CR2; X4 represents N or CR3; and with the proviso that one or two of X1, X2, X3 and X4 represent N; R1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy(lower alkoxy)-substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A- wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R3 represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, or prodrugs thereof which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses and production intermediates thereof.
    本发明提供了一种由通式表示的含氮杂环衍生物: 其中X1和X3分别独立地表示N或CH;X2表示N或CR2;X4表示N或CR3;并且在X1、X2、X3和X4中的一个或两个表示N;R1表示氢原子、卤原子、低碳基、低烷氧基、低烷基、低烷氧基取代的(低碳基)基团、低烷氧基取代的(低烷氧基)基团、低烷氧基(低烷氧基)取代的(低碳基)基团、环状低碳基、卤(低碳基)基团或由通式HO-A-表示的基团,其中A表示低碳亚基、低碳亚氧基或低碳基;R2表示氢原子、卤原子、低碳基、环状低碳基、低烷氧基、基、(低酰基)基、单(低碳基)基或双(低碳基)基;R3表示氢原子或低碳基,或其药学上可接受的盐,或其前药,其用作预防或治疗与高血糖相关的疾病,如糖尿病、糖尿病并发症或肥胖症的药剂,以及包含它们的制药组合物和制药用途和中间体。
  • NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:EP1405859A1
    公开(公告)日:2004-04-07
    The present invention is to provide a nitrogen-containing heterocyclic derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof, which exerts an excellent inhibitory activity in human SGLT2 and is useful as an agent for the prevention or treatment of a disease associated with hyperglycemia such as diabetes etc., or a pharmaceutical composition comprising the same and a pharmaceutical use thereof and a production intermediate thereof. In the general formula (I), X1 and X3 are N or CH; X2 is N or CR2; X4 is N or CR3; and with the proviso that one or two of X1, X2, X3 and X4 are N; and R1, R2 and R3 are a hydrogen atom etc.
    本发明旨在提供一种由通式(I)代表的含氮杂环衍生物或其药学上可接受的盐,或其原药,该衍生物对人SGLT2具有优异的抑制活性,可作为预防或治疗糖尿病等与高血糖相关疾病的药物,或由其组成的药物组合物及其药物用途和其生产中间体。在通式(I)中,X1 和 X3 是 N 或 CH;X2 是 N 或 CR2;X4 是 N 或 CR3;但条件是 X1、X2、X3 和 X4 中的一个或两个是 N;R1、R2 和 R3 是氢原子等。
  • US7271153B2
    申请人:——
    公开号:US7271153B2
    公开(公告)日:2007-09-18
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯